Study Links E-Cigarette Bans to Increased Cigarette Sales

Apr.08.2022
Study Links E-Cigarette Bans to Increased Cigarette Sales
A new study suggests that state-level e-cigarette bans are associated with increased cigarette sales.

According to foreign media reports, a new study suggests that a national ban on e-cigarettes is linked to an increase in cigarette sales. The study, published in the scientific journal "Health Affairs," adds to mounting evidence that banning the sale of e-cigarettes may lead more people to revert back to smoking, which is less safe than using nicotine alternatives.

 

During a three-month study, it was found that an additional 3.4 million cigarette packs were sold through convenience stores across three states.

 

Researchers have used state-level cigarette sales data to discover that Massachusetts, which has implemented a complete ban on nicotine e-cigarettes, has seen a 7.5% increase in per capita cigarette sales compared to expectations. Rhode Island and Washington, which have enacted bans on non-tobacco flavored nicotine e-cigarettes, have an average estimated increase of 4.6% in per capita cigarette sales compared to expectations. Based on actual and estimated cigarette sales, the researchers suggest that an additional 3.4 million cigarette packs were sold in convenience stores across the three states during the three-month study period following the implementation of their respective bans.

 

The study was sponsored by Juul Labs, but has had little impact thus far, possibly due to the belief among many in the tobacco control field that research funded by the industry is biased. This debate may stem from decades of data suppression by big tobacco companies, which has recently resurfaced. For example, the Society for Research on Nicotine and Tobacco (SRNT) now explicitly prohibits industry-sponsored speakers from presenting at its conferences, a move that has led to resignations and condemnation of current tobacco control as "anti-scientific".

 

Researchers examined data from the fall of 2019, when legislators began paying attention to a series of mysterious lung diseases referred to as EVALI, which were quickly associated with e-cigarettes by politicians. Although by November 2019, the Centers for Disease Control and Prevention (CDC) had attributed most cases to contaminated illegal THC cartridges, state governments still stirred up panic and sought emergency bans, which in some cases became permanent.

 

In response to the EVALI outbreak, Massachusetts instituted an emergency ban on all nicotine e-cigarettes starting on September 24, 2019. Rhode Island and Washington followed suit, implementing four-month emergency bans on non-tobacco flavored nicotine e-cigarettes on October 4, 2019, and October 10, 2019, respectively. Massachusetts has since permanently banned the sale of flavored e-cigarette products, including menthol, while Rhode Island and Washington's emergency bans have expired, though a permanent flavor ban remains on the table.

 

Previous research has found similar results to those presented in health value papers.

 

The use of nicotine has not been linked to any diagnosis of EVALI in the field of medicine, but misinformation continues to spread. Under the guidance of sensationalist reporting by policymakers and the media, concerns over the rates of youth vaping have directly sparked fears over deadly vaping products. Misleading information is simple: youth are using e-cigarettes and, in some cases, dying from them. Over two years have passed since the outbreak, and the Centers for Disease Control and Prevention (CDC) in the US have yet to release any formal correction stating that nicotine e-cigarettes are not associated with lung injuries.

 

Previous research has yielded similar results to the findings of a health-focused paper. Co-authors from Boston University published an article in the Harm Reduction Journal indicating that misunderstandings surrounding EVALI (e-cigarette or vaping product use-associated lung injury) – which led to a ban in Massachusetts – appeared to have increased cigarette consumption across Boston. Moreover, Dr. Abigail Friedman from Yale University found in JAMA Pediatrics that after San Francisco banned flavored e-cigarettes and tobacco products, high schoolers in the city were more likely to smoke than their peers in other similar districts across the US.

 

(Source: Filter)

 

Restrictions on vaping products may have unintended consequences, including an increase in cigarette sales. While policymakers have focused on limiting access to e-cigarettes, they may inadvertently be pushing consumers back to traditional tobacco products. This is especially problematic given the well-documented health risks associated with smoking. It remains to be seen whether tighter regulations on vaping will have the intended impact of reducing nicotine addiction overall.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
The Philippines Department of Trade and Industry has placed nicotine pouches under mandatory product certification through Department Administrative Order No. 26-07, Series of 2026. Nicotine pouches must obtain a Philippine Standard, or PS, license before they can be manufactured, imported, packed, distributed or sold in the country. The regime requires testing for nicotine content, pH and water activity, while packaging must disclose nicotine strength, ingredients, allergens, batch information, the PS certification mark and prescribed health warnings. Existing market participants have a 12-month transition period to comply.
Regulations
Oct.12
Product | BAT Expands VELO Peach Ice Medium to FamilyMart Stores Nationwide in Japan
Product | BAT Expands VELO Peach Ice Medium to FamilyMart Stores Nationwide in Japan
British American Tobacco Japan (BAT Japan) expanded VELO Peach Ice Medium to FamilyMart stores nationwide in Japan from September 7, 2026. The oral tobacco product first launched on July 6 and had previously been sold through VELO's official online store, glo Store Ginza and tobacco retailers. It combines peach flavor with menthol cooling at a Medium strength level and is priced at JPY 360. Japanese tobacco retailers list 15 pouches per pack. The move adds the new SKU to an existing nationwide FamilyMart distribution network for VELO rather than marking the brand's first entry into the convenience-store chain.
Sep.15
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Pennsylvania began enforcing its electronic nicotine delivery system directory restrictions on October 19, 2026. Among 163 product listings recorded before enforcement, four CrossBar 20K disposables stood out with 13mL capacity, advertised puff counts of up to 20,000 and a flattened design distinct from conventional pod systems and compact disposables. Historical records identify earlier 1.3mL CrossBar products associated with Romo LLC, while newer 13mL products appeared in several state directories beginning in 2025 under entities including Blue Nine LLC. PMTA compliance expert Mr. K identified amendments and application ownership transfers as possible regulatory mechanisms, although neither has been confirmed in this case. Separately, Reynolds' $7.5 million acquisition of 16 PACHA products and related assets illustrates the commercial value of products linked to historic PMTA submissions.
Special Report
Oct.22
Swedish-Founded Nicotine Pouch Retailer GotPouches Shifts to U.S.-Based Operations, Reaching Over 25 States
Swedish-Founded Nicotine Pouch Retailer GotPouches Shifts to U.S.-Based Operations, Reaching Over 25 States
Swedish-founded online nicotine pouch retailer GotPouches has completed the localization of its U.S. operations under UpNorth Retail LLC, with corporate operations in Franklin, Tennessee, domestic fulfillment from Nashville and U.S.-based customer support. The company says its catalog covers more than 20 nicotine pouch brands and it currently serves customers in more than 25 U.S. states.
Sep.18
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10